Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension

Update Il y a 4 ans
Reference: NCT01223352

Woman and Man

Extract

The primary objective of AC-052-373 was to assess the pharmacokinetic (PK) profile of two dosing regimens of the pediatric formulation of bosentan in children with pulmonary arterial hypertension (PAH) <12 years of age.


Inclusion criteria

  • pulmonary arterial hypertension


Links